This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
J&J Seeks Darzalex's Label Expansion in First-Line Setting
by Zacks Equity Research
Johnson & Johnson (JNJ) has submitted regulatory applications in the United States and EU for label expansion of Darzalex as first-line therapy for multiple myeloma.
J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen
by Zacks Equity Research
J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.
Quality Dividend ETFs to Tackle Uncertainty
by Zacks Equity Research
Consider these 3 dividend ETFs for your portfolio to fight growing market uncertainty.
United Therapeutics PAH Drug's Exclusivity Period Extended
by Zacks Equity Research
United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.
Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU
by Zacks Equity Research
Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.
J&J Presents Positive New Data for Diabetes Drug Invokana
by Zacks Equity Research
Johnson & Johnson (JNJ) puts forth positive data from CANVAS study on its type II diabetes drug, Invokana, showing better renal outcomes.
Achillion (ACHN) Shares Down as J&J Announces Stake Sale
by Zacks Equity Research
Achillion's (ACHN) shares fell following the announcement that J&J will sell its complete stake in the company.
Allergan's Vraylar Gets FDA Nod for Maintenance Therapy
by Zacks Equity Research
Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.
Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis
by Zacks Equity Research
CHMP has given a positive opinion recommending the marketing approval of Merck's (MRK) Prevymis for the prevention of CMV infection.
AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate
by Zacks Equity Research
AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.
Fretting Over Tax Plan Uncertainty? Buy 5 Ultra-Safe Stocks
by Tirthankar Chakraborty
With the markets apprehending a healthy pullback after a strong run, investing in stocks that are immune to market gyrations seems judicious. The best way to go about doing this is by creating a portfolio of ultra-safe stocks.
Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y
by Zacks Equity Research
Impax (IPXL) reported dismal third-quarter results with earnings and sales coming in lower than the year-ago period. However, the company beat estimates on both counts.
AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View
by Zacks Equity Research
AstraZeneca's (AZN) Q3 results were mixed. It expects 2017 core earnings to be toward the favorable end of the guidance range of a decline in low-to-mid teen percentage.
Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus
by Zacks Equity Research
Achillion Pharmaceuticals' (ACHN) third-quarter loss was narrower than estimates. The company is focusing on expanding its key pipeline candidate in several indications.
Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Geron's (GERN) loss per share in the third quarter was narrower than expected. However, revenues missed estimates. Imetelstat remains in focus.
Pfizer (PFE) Beats on Q3 Earnings, Raises 2017 EPS View
by Zacks Equity Research
Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised its adjusted earnings guidance while tightening revenue expectations for 2017.
AbbVie (ABBV) Q3 Earnings Top, Revenues In Line, View Up
by Zacks Equity Research
AbbVie's (ABBV) Q3 earnings surpass estimates with revenues matching the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
What's in the Cards for Geron (GERN) this Earnings Season?
by Zacks Equity Research
With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q3 release.
Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.
Anthem's (ANTM) Q3 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Anthem's (ANTM) strong third-quarter results were driven by solid enrollment growth.
Is a Beat Likely for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q3, genericization of key drugs, pricing pressure and rising competition will hurt sales.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Schlumberger, PayPal, Adobe and Philips
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Schlumberger, PayPal, Adobe and Philips
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew
Biogen (BIIB) Tops Q3 Earnings & Sales, Spinraza Sales Up
by Zacks Equity Research
Biogen (BIIB) exceeds both earnings and sales estimates in the third quarter of 2017. The company's newest drug Spinraza's continual strong performance drives its revenue.
Drug/Biotech Stocks Q3 Earnings on Oct 25: AMGN, GSK, VRTX
by Zacks Equity Research
The pharma/biotech industry has seen a solid start to Q3 earnings as evident from J&J's encouraging results. Let's see if some of the other leading players - Amgen, Glaxo and Vertex - follow suit.